Entrada Therapeutics
TRDA
128 hedge funds and large institutions have $214M invested in Entrada Therapeutics in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 16 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
59% more capital inflows, than outflows
Capital inflows: $42.9M | Capital outflows: $26.9M
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
7% more funds holding
Funds holding: 120 → 128 (+8)
3.83% more ownership
Funds ownership: 71.09% → 74.92% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$12M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.95M |
| 3 |
JP Morgan Chase
New York
|
+$4.62M |
| 4 |
Millennium Management
New York
|
+$2.35M |
| 5 |
BlackRock
New York
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$11.8M |
| 2 |
JHC
Jones Hill Capital
New York
|
-$4.72M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$1.14M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.13M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$826K |
TRDA Hedge Fund Activity: Q2 2026 in Review
128 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q2 2026, worth a combined $214M — down 38% from $343M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TRDA positions and 16 closed out — a net gain of 9 holders — while 55 added to existing stakes and 31 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $12M. The largest seller was TCG Crossover Management, cutting an estimated $11.8M.
- 128 institutional investors held Entrada Therapeutics (TRDA) as of Q2 2026, up from 120 in Q1 2026.
- Funds reported $214M of Entrada Therapeutics stock for Q2 2026, down 38% quarter-over-quarter.
- 25 funds opened new Entrada Therapeutics positions in Q2 2026 and 16 closed out, a net change of +9 holders.
- The largest Entrada Therapeutics buyer in Q2 2026 was MPM BioImpact, an estimated $12M added.
- The largest Entrada Therapeutics seller in Q2 2026 was TCG Crossover Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2026.